HPS Pharmacies wish to advise that Aspen Pharma, in consultation with the Therapeutic Goods Administration (TGA), have given notice of a drug quarantine for Endone® as follows:
Oxycodone hydrochloride 5mg
The only batch affected by this quarantine notice is CW612 with an expiry date of November 2020.
This drug quarantine has been initiated following a single consumer report alleging that a strip of Anamorph® tablets was present in a box of Endone® 5mg tablets. Each Anamorph® tablet contains 30mg of morphine sulfate which is approximately four times the equivalent dose of an Endone® tablet. Therefore, there is a theoretical potential for overdose or adverse effects.
Please inspect your stock and quarantine all affected products until further notice. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined and HPS Pharmacies will arrange for replacement stock as required. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Aspen Pharma on 1300 659 646.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates